English 
Lumbar Radiculopathy (Sciatica)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00
The Lumbar Radiculopathy/LSR (Sciatica) therapeutic market is expected to experience high growth throughout our study period, increasing from 2017 to 2030. The main drivers of this growth will be the launch of new drugs in chronic LSR/sciatica setting, e.g., Dexamethasone sodium phosphate gel / SEMDEXA (Scilex Pharmaceuticals), Condoliase / HERNICORE (Seikagaku Corporation / Ferring Pharmaceuticals), ETX-810 (Eliem Therapeutics Inc), Extended-release Clonidine / Clonidine micropellet (Sollis Therapeutics) and extended-release dexamethasone (SpineThera).
Description
Sciatica (also refferred to as Lumbar Radiculopathy or lumbosacral radiculopathy (LSR) , which is medically defined as lumbar radiculopathy, is nerve pain that originates deep in the buttock and travels down to the thigh and/or leg. Sciatica is commonly caused when a herniated disc or narrowing of the bony opening for spinal nerves (foraminal spinal stenosis) compresses a nerve root in the lumbar spine.
Approximately 90% of cases of sciatica is due to spinal disc herniation pressing on one of the lumbar or sacral nerve roots, followed by spinal stenosis or the narrowing of the spinal canal which is another reason for sciatica pain. Sciatica may also occur during pregnancy and up to 8% cases rarely arises from Piriformis syndrome in which the shortening of piriformis muscle exerts pressure on the sciatic nerve. However, Disc herniation, back sprain, shingles, and degenerative lumbar spine can all cause acute sciatica, lasting from days to weeks, but degeneration of the lumbar spine and discs leads to chronic sciatica that persists unless a surgical intervention is performed. Sciatica is often characterized by extreme pain and inflammation. Sciatica can occur at any age but often affects men beginning in their 40s and women in their 50s and 60s.
Sciatica – Prevalence (Epidemiology)
The criteria used to diagnose Lumbar Radiculopathy (Sciatica) are those of the diagnostic guidelines provided by various governing bodies. According to these criteria and the KOL perspective, there is no specific tests for sciatica and current diagnosis are mainly done by using tools like neuroimaging, MRI scan, CT myelography, Electromyography (EMG), straight leg raising test and Cerebrospinal fluid analysis. As the diagnosis of lumbosacral radiculopathy (Sciatica) is not specific, there are other conditions that can be differentiated due to the radicular pain. The other conditions in the differential diagnosis of lumbosacral radiculopathy include herniated disc, lumbosacral plexopathy, lumbar spinal stenosis, mononeuropathies, diabetic amyotrophy, cauda equina syndrome, and non-radicular back pain.
“The total prevalent cases of lumbosacral radicular pain (LSR) / sciatica in the G7 countries are projected to increase from 24 million in 2017 to XX million by 2030 with a CAGR of XX% for the study period (2017-2030 ). The United States was estimated to have the highest prevalence of lumbar radiculopathy (sciatica) cases in 2017.”
Sciatica – Current Market Size & Forecast Trends
Current market of Sciatica holds treatment options that are supportive like a conservative (nonsurgical) and surgical approaches. Conservative treatment of sciatica further includes physical therapy, behavioral therapies, or pharmacological therapies. Pharmacological therapies includes medications such as non-steroidal anti-inflammatory drugs (NSAIDs), epidural steroid injections (ESIs), opioids etc. that has been used over-the counter and were observed to reduce the swelling and sciatic pain. Patients are treated with a wide variety of medication first and referred for epidural steroid injections as a second step if they fail to respond to pain medication.
“Epidural injections are common. An estimated 10 million to 11 million injections (2.2 million in the Medicare population) are administered annually in the United States. Despite of widespread utilization of ESIs, concerns persist in the market about particulate steroids and potential side effect and safety concerns (e.g., stroke) from current off-label use. As a result, a significant unmet medical need exists within the market for a potent, non-particulate ESI formulation that demonstrates safety and effectiveness in controlled clinical trial evaluations. Therefore, current sciatica market exhibit a critical unmet need to improve the quality of life of the patients since there are no FDA approved therapies to treat the indication and the off-label therapies have several side effects.”
The Lumbar Radiculopathy / LSR (Sciatica) market is expected to see high growth during the forecast period. The market in the G7 countries is expected to reach more than $18 billion in 2032. The lumbar radiculopathy (sciatica) treatment market is divided into acute and chronic lumbar radiculopathy.
“Approximately 70% of acute cases will be recovered with primary treatments and the remaining 30% are expected to fall into the chronic group, referred to here as chronic LSR. “
The market for acute lumbar radiculopathy (Sciatica) is relatively large compared to the market for chronic lumbar radiculopathy (Sciatica) due to the high number of patients and the increase in primary care prescriptions each year.
Report Highlights
- Lumbar Radiculopathy (Sciatica)– Current Market Trends
- Lumbar Radiculopathy (Sciatica)– Current & Forecasted Cases across the G7 Countries
- Lumbar Radiculopathy (Sciatica)– Market Opportunities And Sales Potential for Agents
- Lumbar Radiculopathy (Sciatica)– Patient-based Market Forecast to 2032
- Lumbar Radiculopathy (Sciatica)– Untapped Business Opportunities
- Lumbar Radiculopathy (Sciatica)– Product Positioning Vis-a-vis Competitors’ Products
- Lumbar Radiculopathy (Sciatica)– KOLs Insight
Additional information
| Price | Single User License, 2-3 User License, Site License, Enterprise License |
|---|
Table of Contents
- Executive Summary
- Key Findings
- Lumbar Radiculopathy (Sciatica) Disease Background
- Lumbar Radiculopathy (Sciatica) Definition
- Symptoms & Causes
- Pathophysiology
- Diagnosis & Diagnostic Recommendations
- Differential Diagnosis
- Epidemiology and Patient Populations
- Key Findings
- Methods and data Sources
- Country Specific Prevalent Population (US, Germany, France, Italy, Spain, UK, and Japan)
- Country Specific Chronic Prevalent cases of Lumbar Radiculopathy (Sciatica)
- Country Specific Treated & Refractory Cases of Chronic Lumbar Radiculopathy (Sciatica)
- Key Sources for Lumbar Radiculopathy (Sciatica) Epidemiology and Model Parameters
- United States
- United States Prevalent Population of Lumbar Radiculopathy (Sciatica)
- United States Chronic Prevalent cases of Lumbar Radiculopathy (Sciatica)
- United States Treated & Refractory Cases of Chronic Lumbar Radiculopathy (Sciatica)
- Germany
- Germany Prevalent Population of Lumbar Radiculopathy (Sciatica)
- Germany Chronic Prevalent cases of Lumbar Radiculopathy (Sciatica)
- Germany Treated & Refractory Cases of Chronic Lumbar Radiculopathy (Sciatica)
- France
- France Prevalent Population of Lumbar Radiculopathy (Sciatica)
- France Chronic Prevalent cases of Lumbar Radiculopathy (Sciatica)
- France Treated & Refractory Cases of Chronic Lumbar Radiculopathy (Sciatica)
- Italy
- Italy Prevalent Population of Lumbar Radiculopathy (Sciatica)
- Italy Chronic Prevalent cases of Lumbar Radiculopathy (Sciatica)
- Italy Treated & Refractory Cases of Chronic Lumbar Radiculopathy (Sciatica)
- United States
-
-
- Spain
- Spain Prevalent Population of Lumbar Radiculopathy (Sciatica)
- Spain Chronic Prevalent cases of Lumbar Radiculopathy (Sciatica)
- Spain Treated & Refractory Cases of Chronic Lumbar Radiculopathy (Sciatica)
- United Kingdom
- United Kingdom Prevalent Population of Lumbar Radiculopathy (Sciatica)
- United Kingdom Chronic Prevalent cases of Lumbar Radiculopathy (Sciatica)
- United Kingdom Treated & Refractory Cases of Chronic Lumbar Radiculopathy (Sciatica)
- Japan
- Japan Prevalent Population of Lumbar Radiculopathy (Sciatica)
- Japan Clinical Chronic Prevalent cases of Lumbar Radiculopathy (Sciatica)
- Japan Treated & Refractory Cases of Chronic Lumbar Radiculopathy (Sciatica)
- Spain
-
- Current Therapies and Medical Practice
- Treatments & Medical Practices
- Pharmacological Approaches
- Non-Pharmacological Approaches
- Unmet Needs
- Emerging Therapies
- Pipeline Overview
- Therapeutic Developments Pipeline for Lumbar Radiculopathy (Sciatica)
- Product Analysis
- Dexamethasone sodium phosphate gel (Scilex Pharmaceuticals)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- Condoliase (Seikagaku Corporation)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- Clonidine extended release (Sollis Therapeutics)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- ETX-810 (Eliem Therapeutics Inc)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- Sustained-release dexamethasone (SpineThera)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- BOL-DP-o-04 (Breath of Life International Pharma Ltd)
- Product Profile
- Clinical Development
- KLS-2031 (Kolon Life Science)
- Product Profile
- Clinical Development
- Dexamethasone sodium phosphate gel (Scilex Pharmaceuticals)
- Product Analysis
- Lumbar Radiculopathy (Sciatica)- Pricing & Reimbursement
- Future Treatment Paradigm
- Lumbar Radiculopathy (Sciatica) Competitor Landscape and Approvals Anticipated
- Future Treatment Algorithms and Competitor Positioning
- Key Data Summary for Emerging Treatment
- Annual Cost of Current & Emerging Therapies
- Market Outlook
- Key Findings
- Country Specific Market Forecast to 2032
- Sales of Drugs to Treat Lumbar Radiculopathy (Sciatica) in the Major Pharmaceutical Markets, 2018-2032
- Patient Share of Lumbar Radiculopathy (Sciatica) Therapies and by Drug
- Market Forecast by Country
- United States
- United States Market for Lumbar Radiculopathy (Sciatica) 2022-2032 (USD Million)
- United States Market for Lumbar Radiculopathy (Sciatica) by Therapies 2022-2032 (USD Million)
- Germany
- Germany Market for Lumbar Radiculopathy (Sciatica) 2022-2032 (USD Million)
- Germany Market for Lumbar Radiculopathy (Sciatica) by Therapies 2022-2032 (USD Million)
- France
- France Market for Lumbar Radiculopathy (Sciatica) 2022-2032 (USD Million)
- France Market for Lumbar Radiculopathy (Sciatica) by Therapies 2022-2032 (USD Million)
- Italy
- Italy Market for Lumbar Radiculopathy (Sciatica) 2022-2032 (USD Million)
- Italy Market for Lumbar Radiculopathy (Sciatica) by Therapies 2022-2032 (USD Million)
- Spain
- Spain Market for Lumbar Radiculopathy (Sciatica) 2022-2032 (USD Million)
- Spain Market for Lumbar Radiculopathy (Sciatica) by Therapies 2022-2032 (USD Million)
- United Kingdom
- United Kingdom Market for Lumbar Radiculopathy (Sciatica) 2022-2032 (USD Million)
- United Kingdom Market for Lumbar Radiculopathy (Sciatica) by Therapies 2022-2032 (USD Million)
- Japan
- Japan Market for Lumbar Radiculopathy (Sciatica) 2022-2032 (USD Million)
- Japan Market for Lumbar Radiculopathy (Sciatica) by Therapies 2022-2032 (USD Million)
- United States
- Market Drivers and Constraints
- What Factors Are Driving the Market for Lumbar Radiculopathy (Sciatica)?
- What Factors Are Constraining the Market for Lumbar Radiculopathy (Sciatica)?
Sample Enquiry
Related products
-
Head and neck squamous cell carcinoma (HNSCC)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2033
$7,500.00 – $22,500.00Select optionsAccording to Mellalta Meets Analyst’s most recent estimate, the Head and neck squamous cell carcinoma (HNSCC) therapeutics market for HNSCC s was worth US$ Billion in 2023 and is predicted to grow at a 13.9% CAGR to reach US$ 7.5 Billion by 2033.
-
Central Precocious Puberty | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00Select optionsGrowth of the diagnosed CPP population will contribute to increasing sales in the CPP therapy market over our forecast period. An estimated annual growth rate of 0.12% in the diagnosed CPP population across the major pharmaceutical markets will contribute to increasing CPP therapy sales. In 2022, there were approximately xx diagnosed cases of CPP in the major markets; we expect the number of cases will exceed xx in 2032 owing to changes in population demographics and increasing awareness related to this rare disease.Strong Uptake of the 6-months Leuprolide acetate (Fensolvi) will be driven by the need for an alternative therapy for 3-months depot Leuprolide acetate and will contribute to the growth of the CPP market. We expect leuprolide acetate to be preferentially prescribed to patients. However, as physicians become more familiar with the agent, we expect Fensolvi to gain more patient share. The drug is forecasted to earn sales of $xx million in 2032. -
HER2-Low Gastric / Gastroesophageal Junction (GEJ) Adenocarcinoma | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2034
$6,989.00 – $20,967.00Select optionsAccording to Mellalta Meets Analyst’s most recent estimate, the HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma therapeutics market was worth US$ Billion in 2023 and is predicted to grow at a XX% CAGR to reach US$ Billion by 2034.
-
Metastatic Renal cell carcinoma (mRCC) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsCurrently, tyrosine kinase inhibitors (TKIs) and anti-VEGF antibodies are widely used in first- and second-line treatments for mRCC. Despite the current treatments, there remains the unmet need for early diagnosis and treatment options. Emerging drugs in development like Dovitinib (Allarity Therapeutics) and Savolitinib/ AZD6094 (Astrazeneca), and others will expand the first-line and second-line settings for patients with mRCC and likely to address the current unmet needs for the treatment of mRCC. The upcoming treatment options for mRCC can drive market competition, contributing to budget sustainability and improving patient access to biologic treatments.